[Federal Register: March 30, 2006 (Volume 71, Number 61)]
[Notices]
[Page 16136-16137]
[DOCID:fr30mr06-53]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP05-32-002]

Northwest Pipeline Corporation; Notice of Amendment

March 23, 2006.
    Take notice that on March 16, 2006, Northwest Pipeline Corporation
(Northwest), 295 Chipeta Way, Salt Lake City, Utah 84158, filed in
Docket No. CP05-32-002, an application pursuant to sections 7(b) and
(c) of the Natural Gas Act (NGA) to amend the certificate of public
convenience and necessity that was issued for its Capacity Replacement
Project by Commission order dated September 13, 2005 in Docket Nos.
CP05-32-001 and CP05-32-001, all as more fully set forth in the request
which is on file with the Commission and open to public inspection.
    Specifically, Northwest requests that the Commission authorize
minor scope changes for its Capacity Replacement Project, including:
(i) Abandonment by removal of three additional segments of 26-inch
diameter pipeline, totaling 0.20 miles; (ii) abandonment of related
connection facilities at eight additional locations, elimination of
such abandonments at seven previously authorized locations, and
correction of the abandonment descriptions for two previously
authorized locations; and (iii) the elimination of a previously
authorized 30-inch diameter valve on Northwest's existing 30-inch
diameter mainline.
    Any questions regarding this application should be directed to Gary
K. Kotter, Manager, Certificates and Tariffs-3C1, Northwest Pipeline
Corporation, P.O. Box 58900, Salt Lake City, Utah 84158-0900, at (801)
584-7117 or fax<PHONE_NUMBER>.
    There are two ways to become involved in the Commission's review of
this project. First, any person wishing to obtain legal status by
becoming a party to the proceedings for this project should, on or
before the comment date stated below, file with the Federal Energy
Regulatory Commission, 888 First Street, NE., Washington, DC 20426, a
motion to intervene in accordance with the requirements of the
Commission's Rules of Practice and Procedure (18 CFR 385.214 or
385.211) and the Regulations under the NGA (18 CFR 157.10). A person
obtaining party status will be placed on the service list maintained by
the Secretary of the Commission and will receive copies of all
documents filed by the applicant and by all other parties. A party must
submit 14 copies of filings made with the Commission and must mail a
copy to the applicant and to every other party in the proceeding. Only
parties to the proceeding can ask for court review of Commission orders
in the proceeding.
    However, a person does not have to intervene in order to have
comments considered. The second way to participate is by filing with
the Secretary of the Commission, as soon as possible, an original and
two copies of comments in support of or in opposition to this project.
The Commission will consider these comments in determining the
appropriate action to be taken, but the filing of a comment alone will
not serve to make the filer a party to the proceeding. The Commission's
rules require that persons filing comments in opposition to the project
provide copies of their protests only to the party or parties directly
involved in the protest.
    Persons who wish to comment only on the environmental review of
this project should submit an original and two copies of their comments
to the Secretary of the Commission. Environmental commentors will be
placed on the Commission's environmental mailing list, will receive
copies of the environmental documents, and will be notified of meetings
associated with the Commission's environmental review process.
Environmental commentors will not be

required to serve copies of filed documents on all other parties.
However, the non-party commentors will not receive copies of all
documents filed by other parties or issued by the Commission (except
for the mailing of environmental documents issued by the Commission)
and will not have the right to seek court review of the Commission's
final order.
    Comments, protests and interventions may be filed electronically
via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and
the instructions on the Commission's Web site under the ``e-Filing''
link.
    Comment Date: April 13, 2006.

Magalie R. Salas,
Secretary.
 [FR Doc. E6-4589 Filed 3-29-06; 8:45 am]

BILLING CODE 6717-01-P


[Federal Register Volume 85, Number 58 (Wednesday, March 25, 2020)]
[Notices]
[Pages 16949-16950]
[FR Doc No: 2020-06222]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. FDA-2020-D-1136, FDA-2020-D-1137, FDA-2020-D-1138, FDA-
2020-D-1139, FDA-2020-D-1140, FDA-2020-D-1141, FDA-2020-D-1142, and
FDA-2020-D-1143]

Process for Making Available Guidance Documents Related to
Coronavirus Disease 2019

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the process for making available FDA guidance documents related to the
Coronavirus Disease 2019 (COVID-19) public health emergency. FDA
believes that this process will allow the Agency to rapidly disseminate
essential Agency recommendations and policies related to COVID-19 to
industry, FDA staff, and other stakeholders.

FOR FURTHER INFORMATION CONTACT: Kimberly Thomas, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6220, Silver Spring, MD 20993-0002, 301-
796-2357; Stephen Ripley, Center for Biologics Evaluation and Research,
Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm.
7268, Silver Spring, MD 20993-0002,<PHONE_NUMBER>; Erica Takai, Center
for Devices and Radiological Health, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 66, Rm. 5456, Silver Spring, MD 20993-
0002,<PHONE_NUMBER>; Phil Chao, Center for Food Safety and Applied
Nutrition, Food and Drug Administration, CPK1 Rm. 1C001, College Park,
MD 20740,<PHONE_NUMBER>; Diane Heinz, Center for Veterinary Medicine,
Food and Drug Administration, 7500 Standish Pl., MPN2 RME435, HFV-6,
Rockville, MD 20855,<PHONE_NUMBER>; May Nelson, Center for Tobacco
Products, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
75, Rm. 4420, Silver Spring, MD 20993-0002,<PHONE_NUMBER>; John Weiner,
Office of the Commissioner, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 32, Rm. 5130; Silver Spring, MD 20993-0002, 301-
796-8941; or Erik Mettler, Office of Regulatory Affairs, Food and Drug
Administration, 12420 Parklawn Dr., ELEM Rm. 3008, Rockville, MD 20857,
301-796-9254.

SUPPLEMENTARY INFORMATION:

I. Background

    On January 31, 2020, as a result of confirmed cases of COVID-19,
and after consultation with public health officials as necessary, Alex
M. Azar II, Secretary of Health and Human Services, pursuant to the
authority under section 319 of the Public Health Service Act (42 U.S.C.
247), determined that a public health emergency exists and has existed
since January 27, 2020, nationwide.\1\ On March 13, 2020, President
Donald J. Trump declared that the COVID-19 outbreak in the United
States constitutes a national emergency, beginning March 1, 2020.\2\
FDA is committed to providing timely recommendations, regulatory
advice, guidance, and technical assistance on an Agency-wide basis on
issues related to COVID-19, including to clarify our expectations
regarding regulatory requirements to support response efforts to this
emergency. To this end, FDA is announcing procedures for making
available FDA guidance documents related to the COVID-19 public health
emergency. FDA believes that these procedures, which operate within
FDA's established good guidance practices regulations, will allow the
Agency to rapidly disseminate Agency recommendations and policies
related to COVID-19 to industry, FDA staff, and other stakeholders.
---------------------------------------------------------------------------

    \1\ Determination that a Public Health Emergency Exists (January
31, 2020), available at https://www.phe.gov/emergency/news/healthactions/phe/Pages/2019-nCoV.aspx.
    \2\ Proclamation on Declaring a National Emergency Concerning
the Novel Coronavirus Disease (COVID-19) Outbreak (March 13, 2020),
available at https://www.whitehouse.gov/presidential-actions/proclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak/.
---------------------------------------------------------------------------

II. Procedures for Making COVID-19-Related Guidance Documents Available

    To facilitate issuance of guidance on topics related to the COVID-
19 public health emergency, the Agency intends to use the following
procedures:
     In light of the need to act quickly and efficiently to
respond to the COVID-19 public health emergency, FDA anticipates that
prior public participation will not be feasible or appropriate before
FDA implements COVID-19-related guidance documents. FDA anticipates it
will issue COVID-19-related guidance documents for immediate
implementation without prior public comment (see section 701(h)(1)(C)
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 371(h)(1)(C))
and 21 CFR 10.115(g)(2) (Sec.  10.115(g)(2)).
     Although FDA expects that COVID-19-related guidances will
be implemented without prior comment, FDA will solicit comment, review
all comments received, and revise the guidance documents as appropriate
(see Sec.  10.115(g)(2)). Each guidance will specify the docket
number(s) to which comments can be submitted.
     Guidance documents related to COVID-19 will be accessible
on the internet from the FDA web page entitled ``Coronavirus Disease
2019 (COVID-19),'' available at https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/coronavirus-disease-2019-covid-19.
     Guidance documents related to COVID-19 may also be
accessed from the FDA web page entitled ``Search for FDA Guidance
Documents'' available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents.
     Rather than publishing a separate Notice of Availability
(NOA) for each COVID-19-related guidance document, FDA intends to
publish periodically a consolidated NOA. This periodic NOA will
announce the availability of all the COVID-19-related guidance
documents that issued during the relevant period. The consolidated NOA
will provide instructions to the public on submitting comments on
COVID-19-related guidance documents, including the docket number(s)
associated with each guidance document, information on how to view the
dockets, and instructions for persons interested in obtaining a copy of
a COVID-19-related guidance document. In addition, the guidance
document will provide information to the public on submitting comments
on the guidance document, including the docket number(s) associated
with the guidance document and instructions for persons interested in
obtaining a copy of a COVID-19-related guidance document.
     FDA intends to establish one docket for each Center or
Office that may issue

COVID-19-related guidance documents. All COVID-19-related guidance
documents issued by that Center or Office will be available in the
docket associated with the Center or Office that issues the guidance
document. The docket numbers associated with each Center or Office that
may issue COVID-19-related guidance documents are as follows:

------------------------------------------------------------------------
 Title of Docket (for each Center or
               Office)                             Docket No.
------------------------------------------------------------------------
Center for Drug Evaluation and         FDA-2020-D-1136
 Research (CDER) COVID-19.
Center for Biologics Evaluation and    FDA-2020-D-1137
 Research (CBER) COVID-19.
Center for Devices and Radiological    FDA-2020-D-1138
 Health (CDRH) COVID-19.
Center for Food Safety and Applied     FDA-2020-D-1139
 Nutrition (CFSAN) COVID-19.
Center for Veterinary Medicine (CVM)   FDA-2020-D-1140
 COVID-19.
Center for Tobacco Products (CTP)      FDA-2020-D-1141
 COVID-19.
Office of the Commissioner (OC) COVID- FDA-2020-D-1142
 19.
Office of Regulatory Affairs (ORA)     FDA-2020-D-1143
 COVID-19.
------------------------------------------------------------------------

    Dated: March 20, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-06222 Filed 3-20-20; 11:15 am]
 BILLING CODE 4164-01-P